Vericel (VCEL) Tops Q2 EPS by 7c; Offers Guidance-

Vericel (NASDAQ: VCEL) reported Q2 EPS of $0.04, $0.07 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $77.45 million versus the consensus estimate of $72.7 million.

Outlook FY2026-

Revenue between $330 million to $340 million versus consensus $332.2 million.

For earnings history and earnings-related data on Vericel (VCEL) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94